Thursday, June 18, 2020 3:08:25 PM
Securities Act Rule 144
Selling restricted or control securities in the marketplace can be a complicated process. This is because the sales are so close to the interests of the issuing company that the law might require them to be registered. Under Section 5 of the Securities Act of 1933, all offers and sales of securities must be registered with the SEC or qualify for some exemption from the registration requirements. If you have acquired restricted securities or hold control securities and want to publicly sell them, you may need to make special efforts to show that your public sales are exempt from registration.
Rule 144 provides an exemption and permits the public resale of restricted or control securities if a number of conditions are met, including how long the securities are held, the way in which they are sold, and the amount that can be sold at any one time. But even if you’ve met the conditions of the rule, you can’t sell your restricted securities to the public until you’ve gotten a transfer agent to remove the legend.
For more information about selling your restricted or control securities, read our overview, Rule 144: Selling Restricted and Control Securities.
https://www.sec.gov/fast-answers/answersrule144htm.html#:~:text=Rule%20144%20provides%20an%20exemption,sold%20at%20any%20one%20time.
Selling restricted or control securities in the marketplace can be a complicated process. This is because the sales are so close to the interests of the issuing company that the law might require them to be registered. Under Section 5 of the Securities Act of 1933, all offers and sales of securities must be registered with the SEC or qualify for some exemption from the registration requirements. If you have acquired restricted securities or hold control securities and want to publicly sell them, you may need to make special efforts to show that your public sales are exempt from registration.
Rule 144 provides an exemption and permits the public resale of restricted or control securities if a number of conditions are met, including how long the securities are held, the way in which they are sold, and the amount that can be sold at any one time. But even if you’ve met the conditions of the rule, you can’t sell your restricted securities to the public until you’ve gotten a transfer agent to remove the legend.
For more information about selling your restricted or control securities, read our overview, Rule 144: Selling Restricted and Control Securities.
https://www.sec.gov/fast-answers/answersrule144htm.html#:~:text=Rule%20144%20provides%20an%20exemption,sold%20at%20any%20one%20time.
Give me a Member Mark if you want to track WINNERS and I will follow you back!
Recent MAJI News
- NexTel Medical Corp Enters Final Stage for Commercial Launch; Sets Sights on Revenue Generation and OTCQB Uplist • GlobeNewswire Inc. • 05/11/2026 03:53:17 PM
- NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test • GlobeNewswire Inc. • 04/07/2026 02:30:00 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/30/2026 04:15:02 AM
- Form 253G1 - • Edgar (US Regulatory) • 03/27/2026 07:12:08 PM
- Form 1-A POS - • Edgar (US Regulatory) • 03/26/2026 08:25:15 PM
- Form 1-A POS - • Edgar (US Regulatory) • 03/20/2026 08:23:33 PM
- Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value • GlobeNewswire Inc. • 03/16/2026 02:15:00 PM
- Form 1-A POS - • Edgar (US Regulatory) • 03/11/2026 07:11:39 PM
- Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions • GlobeNewswire Inc. • 03/05/2026 06:00:20 PM
- Form 1-A POS - • Edgar (US Regulatory) • 02/19/2026 09:39:04 PM
- Form 253G2 - • Edgar (US Regulatory) • 02/11/2026 08:06:08 PM
- Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition • GlobeNewswire Inc. • 02/10/2026 03:30:00 PM
- Form 253G2 - • Edgar (US Regulatory) • 01/15/2026 06:47:01 PM
- Form 253G1 - • Edgar (US Regulatory) • 01/14/2026 09:54:45 PM
- Form 1-A POS - • Edgar (US Regulatory) • 12/31/2025 12:32:47 PM
- Form 253G2 - • Edgar (US Regulatory) • 12/29/2025 08:29:49 PM
- Exousia Pro, Inc. Announces Executed LOI for Strategic Acquisition of High-Revenue Telehealth Platform to Accelerate Nutraceutical Commercialization • ACCESS Newswire • 12/11/2025 05:15:00 PM
- Exousia Pro, Inc. Revolutionizes Nutraceuticals With Launch Of Maxasome(TM): The First All-Natural, Biologically Active Exosomal Supplement • ACCESS Newswire • 12/05/2025 04:00:00 PM
- Form 253G2 - • Edgar (US Regulatory) • 12/04/2025 09:35:28 PM
- Exousia Pro, Inc. Completes Exclusive Licensing Agreement With the University of Central Florida for Novel Cancer Diagnostic and Therapy Platforms • ACCESS Newswire • 12/02/2025 06:45:00 PM
- Exousia Pro Initiates Strategic Realignment, Acquires Controlling Stake in SEC-Reporter Lamy (LMMY) in All-stock Exchange Transaction for Exousia AI, to Advance Growth and Enhance Shareholder Value • ACCESS Newswire • 11/17/2025 08:40:00 PM
- Exousia Pro Announces Breakthrough In Exosome-Based Delivery • ACCESS Newswire • 11/04/2025 03:40:00 PM
- Exousia Pro is Excited to Announce that it has Received Orphan Drug Designation from the FDA • ACCESS Newswire • 10/28/2025 02:20:00 PM
- Exousia Pro Announces Groundbreaking Study to Revolutionize the Global Edibles Market with CBD-Loaded Exosomes • ACCESS Newswire • 09/29/2025 04:35:00 PM
